Elizabeth M. Gaughan

发表

Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.

Paul R. Kunk, C. Slingluff, R. Gentzler, 2016, Immunotherapy.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Hung-Ming Wang, R. Greil, K. Harrington, 2019, The Lancet.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

J. Shabanowitz, D. Hunt, V. Engelhard, 2020, Journal for immunotherapy of cancer.

Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer.

J. Warner, D. Costa, Elizabeth M. Gaughan, 2011, Journal of thoracic disease.

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

N. Wages, C. Slingluff, W. Grosh, 2019, Journal of Immunotherapy for Cancer.

Human immunodeficiency virus--associated renal cell carcinoma: a transatlantic case series.

L. Pantanowitz, T. Powles, J. Stebbing, 2008, Clinical genitourinary cancer.

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

J. Wolchok, J. Kirkwood, H. Zarour, 2021, Oncoimmunology.

Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series

M. Salerno, C. Slingluff, R. Gentzler, 2020, Cardio-Oncology.

Bilateral Mydriasis and Serous Retinal Detachments Associated With Ipilimumab and 6-Melanoma Helper Peptide Vaccine for Cutaneous Melanoma.

S. Newman, Elizabeth M. Gaughan, Y. Shildkrot, 2019, JAMA ophthalmology.

Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature

Paul R. Kunk, C. Slingluff, Elizabeth M. Gaughan, 2016, Journal of Immunotherapy for Cancer.

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)

C. Slingluff, W. Grosh, W. Olson, 2022, Journal for ImmunoTherapy of Cancer.

Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?

O. Olopade, W. Foulkes, K. Offit, 2013, Breast Cancer Research and Treatment.

Sarcoidosis, malignancy and immune checkpoint blockade.

Elizabeth M. Gaughan, 2017, Immunotherapy.

Outcomes From Cytotoxic Chemotherapy Following Progression on Immunotherapy in Metastatic Melanoma: An Institutional Case-Series

Elizabeth M. Gaughan, B. Horton, 2022, Frontiers in Oncology.

Salvage combination ipilimumab and nivolumab after failure of prior checkpoint inhibitor therapy in patients with advanced melanoma.

C. Slingluff, W. Grosh, G. Petroni, 2017 .

Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers

S. Schnitt, J. Garber, N. Tung, 2014, Breast Cancer Research and Treatment.

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.

B. Yeap, D. Costa, Sarah K. Cryer, 2013, Lung cancer.

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities

D. Costa, Elizabeth M. Gaughan, 2011, Therapeutic advances in medical oncology.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma

J. Witte, T. Ho, J. Kim, 2018, Clinical Cancer Research.

HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management

L. Pantanowitz, Elizabeth M. Gaughan, B. Dezube, 2009, BMC urology.

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma

S. Patel, P. Hwu, N. Wages, 2021, Journal for ImmunoTherapy of Cancer.

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

N. Wages, W. Grosh, W. Olson, 2021, Journal for ImmunoTherapy of Cancer.

Primary Cutaneous Small/Medium CD4+ T-CELL Lymphoproliferative Disorder Occurring in a Patient With Metastatic Melanoma.

Elizabeth M. Gaughan, A. Gru, Jonathan J Davick, 2018, The American Journal of dermatopathology.

Optimizing Endocrine Therapy for Metastatic Breast Cancer

S. Come, Elizabeth M. Gaughan, 2012, Current Breast Cancer Reports.

Regression of an intramedullary spinal cord metastasis with a checkpoint inhibitor: a case report.

D. Schiff, Elizabeth M. Gaughan, A. Gru, 2017, CNS oncology.

PD-L1 and MHC Class I Expression in High-grade Ovarian Cancers, Including Platinum-resistant Recurrences Treated With Checkpoint Inhibitor Therapy

A. Mills, Elizabeth M. Gaughan, K. Ring, 2023, Applied immunohistochemistry & molecular morphology : AIMM.

Thymic carcinoma with brain metastases: A rare presentation of a rare malignancy

D. Costa, Elizabeth M. Gaughan, P. VanderLaan, 2016 .

Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice

D. Tyler, C. Slingluff, Elizabeth M. Gaughan, 2022, Annals of surgery.

Relevance of the Updated Recursive Partitioning Analysis (U-RPA) Classification in the Contemporary Care of Patients with Brain Metastases

J. Sheehan, C. Fadul, W. Novicoff, 2023, Cancers.

337 Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic durvalumab

I. Puzanov, C. Slingluff, P. Friedlander, 2021, Journal for ImmunoTherapy of Cancer.

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.

B. Yeap, D. Costa, Sarah K. Cryer, 2013, Lung Cancer.

Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.

C. Slingluff, R. Gentzler, R. Hall, 2016, Immunotherapy.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Second primary ipsilateral breast cancer with contralateral axillary involvement: a case report and literature review.

N. Tung, Elizabeth M. Gaughan, C. Herold, 2011, Clinical breast cancer.

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma

Elizabeth M. Gaughan, Sarah E Gradecki, N. Dar, 2023, Frontiers in oncology.